Journals / Ulusal Romatoloji Dergisi / 2022 / Cilt: 14 - Sayı: 2

Relationship between antibodies and clinical manifestations in systemic lupus erythematosus

Sistemik lupus eritematozusta antikor ve klinik bulgular arasındaki ilişkinin araştırılması

Pages
66–73
Publication Date
2022-11-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Presence of antibodies against ENAs may predict findings that may occur in the follow-up in patients with SLE and It may be useful for follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the role between antibodies to extractable nuclear antigens (ENA) and clinical manifestations in a cohort of systemic lupus erythematosus (SLE) patients.
📊
Key Findings & Data:Methods: The study included 187 adult patients with a diagnosis of SLE.
💡
Conclusion & Impact:Conclusion: Presence of antibodies against ENAs may predict findings that may occur in the follow-up in patients with SLE and It may be useful for follow-up.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the role between antibodies to extractable nuclear antigens (ENA) and clinical manifestations in a cohort of systemic lupus erythematosus (SLE) patients. Methods: The study included 187 adult patients with a diagnosis of SLE. Patients fulfilled the 2012 classification criteria for SLE. Full medical history, general examination, and laboratory investigations were recorded. Analyses of the autoantibodies [antinuclear antibody, antidsDNA, anti-Ro/SSA, anti-La/SSB, anti-Sm and anti-ribonucleoproteins (RNP)] in the serum of the patients at diagnosis were also undertaken by the routine clinical immunology laboratory at University Hospital. Results: The median age was 38 years, and 176 (94.1%) patients were women. Median disease duration was 120 months. Median levels of serum anti-dsDNA, complement 3 and 4 were found 211,7 IU/μL,78 mg/dL and 12,3 mg/dL. The most frequent clinical manifestation of these patients was musculoskeletal disorders (60.4%) the others were mucocutanous disorders, respectively (57.8%), nephritis (37.4%), haematological (18.7%), neurological disorders (12.3%). Anti-Sm, anti-RNP, anti-Ro and anti-La positivity were found in 15%, 24%, 26.7% and 11,8% of SLE cases. Multivariable analysis revealed that discoid rash was independent predictors of anti-Sm positivity; Raynaud phenomenon and oral ulcer were independent predictors of anti-RNP positivity; alopecia, lupus pneumonia and pericarditis were independent predictors of anti-Ro positivity and pleuritis was independent predictors of anti-La positivity. Conclusion: Presence of antibodies against ENAs may predict findings that may occur in the follow-up in patients with SLE and It may be useful for follow-up.

Özet

Amaç: Bu çalışmanın amacı ekstrakte edilebilir nükleer antikorlar (ENA) ile sistemik lupus eritematozus (SLE) hastalarından oluşan bir kohorttaki klinik belirtiler arasındaki ilişkiyi araştırmaktır. Yöntem: Çalışmaya romatoloji polikliniğinde takip edilen 2012 SLE sınıflandırma kriterlerini karşılayan 187 erişkin hasta dahil edildi. Ayrıntılı tıbbi öykü, muayene ve laboratuvar incelemeleri kaydedildi. Hastaların tanı anında serumlarında bulunan otoantikorların [antinükleer antikor, anti-dsDNA, anti-Ro/SSA, anti-La/SSB, anti-Sm ve anti-ribonükleoproteinler (RNP)] analizleri üniversite hastanesi rutin klinik immünoloji laboratuvarı tarafından yapıldı. Bulgular: Ortanca yaş 38 yıldı ve 176 (%94,1) hasta kadındı. Ortanca hastalık süresi ise 120 aydı. Ortalama serum anti-dsDNA, kompleman 3 ve 4 seviyeleri sırasıyla 211,7 IU/μL,78 mg/dL ve 12,3 mg/dL olarak bulundu. Bu hastalarda en sık görülen klinik bulgu musküloskletal bozukluklar (%60,4), sonrasında sırası ile mukokutanöz bozukluklar (%57,8), nefrit (%37,4), hematolojik (%18,7) ve nörolojik bozukluklar olarak görüldü (%12,3). SLE olgularının sırasıyla %15, %24, %26,7 ve %11,8’inde anti-Sm, anti-RNP, anti-Ro ve anti-La pozitifliği vardı. Çok değişkenli analizde diskoid raşın anti-Sm pozitifliği ile, Raynaud fenomeninin ve oral ülserin anti-RNP pozitifliğiyle, alopesi, lupus pnömonisi ve perikarditin anti-Ro pozitifliğiyle ve plöritin anti- La pozitifliği ile ilişkili olduğu gösterilmiştir. Sonuç: ENA’lara karşı oluşan antikorların varlığı SLE’li hastaların takibinde oluşabilecek bulguları predikte edebilir ve takipte yarar sağlayabilir.

🔖

Cite This Article

SALMAN, R. B., HAZNEDAROĞLU, S. (2022). Relationship between antibodies and clinical manifestations in systemic lupus erythematosus. Ulusal Romatoloji Dergisi, Cilt: 14 - Sayı: 2, 66–73. https://ajindex.com/articles/655402

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Wallace DJ, Hahn B. Dubois’ lupus erythematosus: Lippincott Williams & Wilkins; 2007
  2. Fredi M, Cavazzana I, Quinzanini M, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 2014;23:672-7
  3. Bai Y, Tong Y, Liu Y, Hu H. Self-dsDNA in the pathogenesis of systemic lupus erythematosus. Clin Exp Immunol 2018;191:1-10
  4. Aringer M. EULAR/ACR classification criteria for SLE. Seminars in arthritis and rheumatism 2019;49:S14-s7. Epub 2019/11/30
  5. Agarwal S, Harper J, Kiely P. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus 2009;18:407-12
  6. Bentow C, Swart A, Wu J, et al. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta 2013;424:141-7
  7. Davis JM, Moder KG, Homburger HA, Ytterberg SR. Clinical features of 39 patients with antibodies to extractable nuclear antigens despite negative antinuclear antibodies: evidence for autoimmunity including neurologic and connective tissue diseases. Medicine (Baltimore) 2005;84:208-17
  8. Schur PH. Laboratory evaluation of patients with systemic lupus erythematosus. Systemic lupus erythematosus: Elsevier; 2011. p. 629-53
  9. Colglazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: a practical review. South Med J 2005;98:185-91
  10. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005;38:47-54
  11. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
  12. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33
  13. Vlachoyiannopoulos P, Tzavara V, Dafni U, Spanos E, Moutsopoulos H. Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic. J Rheumatol 1998;25:886-91
  14. Satoh M, Yamagata H, Watanabe F, et al. Development of anti- Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with longstanding Sjögren’s syndrome. Lupus 1995;4:63-5
  15. Gaither K, Fox O, Yamagata H, Mamula M, Reichlin M, Harley J. Implications of anti-Ro/Sjögren’s syndrome A antigen autoantibody in nor